Author

Rosemary J. Huggins

University of ChicagoORCID 0000-0002-5524-0920Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cell type annotation· 2 Organism:human· 2 Approach:statistical model· 2 Assay:bulk RNA-seq· 1 Approach:deep learning· 1 Research Focus:differential expression· 1 Research Focus:drug response / drug discovery· 1 Assay:scRNA-seq· 1

Frequent Co-Authors

Geoffrey L. GreeneiD· 2 shared Amy R. DwyeriD· 1 shared Andre Kajdacsy‐BallaiD· 1 shared Carlos Jesus Perez KerkvlietiD· 1 shared Carol Ann LangeiD· 1 shared Debra A. TonettiiD· 1 shared Ellie Piepgras· 1 shared Fouad AlaniiD· 1 shared

Activity by Year

2026-2026 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 25 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

Geoffrey L. GreeneORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Cancer BiologybioRxivPreprintSep 16, 2026

Integrative pipeline to profile and target endocrine therapy-insensitive cell populations in ER+ breast cancer

Svetlana E. Semina, Rosemary J. Huggins, Huiping Zhao…·Jonathan L. Coloff

The paper develops an analytical pipeline to identify and target endocrine therapy-insensitive cells in ER+ breast cancer using single-cell RNA sequencing and functional validation in organoid models.

DOI 10.64898/2026.09.10.750719

humanscRNA-seq

𝕏 PostBluesky

Cancer Biologynpj Breast CancerPeer-reviewedApr 7, 2026

Progesterone receptors drive advanced breast cancer phenotypes including circulating tumor- and stem-like cell expansion in the context of ESR1 mutation

Thu Ha Truong, Noelle E. Gillis, Amy R. Dwyer…·Carol Ann Lange

This study shows that progesterone receptors (PR) interact with mutant ESR1 variants in ER+ breast cancer, driving CSC expansion and UPR activation, which can be targeted therapeutically.

DOI 10.1038/s41523-026-00939-8

humanbulk RNA-seq

𝕏 PostBluesky